FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904914487> ?p ?o ?g. }

• W2904914487 endingPage "669" @default.
• W2904914487 startingPage "664" @default.
• W2904914487 abstract "Prostate cancer (PC) suspicion is based on prostate-specific antigen (PSA) and digital rectal examination (DRE). Multiparametric magnetic resonance imaging (mpMRI) increases prostate biopsy (PBx) specificity and sensitivity for detection of aggressive PC.To identify who benefits from mpMRI according to biopsy scenario (initial biopsy [IBx] vs repeated biopsy [RBx]) and the risk of aggressive PC according to PSA-DRE groups (G1, PSA <10ng/ml and -DRE; G2, PSA <10ng/ml and +DRE; G3, PSA ≥10ng/ml and -DRE; G4, PSA ≥10ng/ml and +DRE).We carried out a retrospective analysis for 768 consecutive men with PC suspicion and scheduled for PBx in a referral institution in 2016 and 2017.Pelvic 3-T mpMRI scanning, targeted biopsy (TBx) for suspicious lesions (Prostate Imaging-Reporting and Data System [PI-RADS] score >1), and 12-core systematic biopsy (SBx).We measured the rate of PBx procedures that could be avoided and the rate of high-grade PC (HGPC) that would be missed among men with negative mpMRI, and the increase in HGPC detection due to TBx. Univariate and multivariate analyses were performed.The rate of avoidable biopsies (PI-RADS <3) was 24.2% overall, with 25.7% for IBx and 20.5% for RBx (p=0.057). The IBx and RBx rates were 31.2% and 19.8% in G1, 13.5% and 30.4% in G2, 23.7% and 21.9% in G3, and 2.5% and 0% in G4, respectively. The overall rate of missed HGPC was 1.0% for IBx and 6.5% for RBx (p=0.170), while the IBx and RBx rates were 1.1% and 5.2% for G1, 2.0% and 11.1% for G2, 0% and 7.7% for G3, and 0% and 0% for G4, respectively (p<0.001). The rate of HGPC (PI-RADS 3-5) diagnosed following TBx increased to 23.9% for IBx and to 32.6% for RBx overall (p<0.001), while the IBx and RBx rates were 29.0% and 45.5% for G1, 20.0% and 33.3% for G2, 40.0% and 38.9% for G3, and 0% and 0% for G4, respectively (p<0.001). Limitations are the single-institution design, the lack of randomisation, and small samples for subgroup analyses.mpMRI was of no benefit for men with PSA ≥10ng/ml and +DRE. Among the other men, mpMRI was of benefit in IBx and RBx as would reduce the biopsy rate by up to 25.7% and increase the net HGPC detection rate by up to 28.4%.All men with suspected prostate cancer could benefit from multiparametric prostate cancer and targeted biopsy except for those with prostate-specific antigen ≥10ng/ml and positive digital rectal examination. The benefits include avoiding unnecessary prostate biopsy procedures and increasing the detection of aggressive cancer." @default.
• W2904914487 created "2018-12-22" @default.
• W2904914487 creator A5004617137 @default.
• W2904914487 creator A5009118055 @default.
• W2904914487 creator A5016719534 @default.
• W2904914487 creator A5025981932 @default.
• W2904914487 creator A5045999238 @default.
• W2904914487 creator A5055737222 @default.
• W2904914487 creator A5057473966 @default.
• W2904914487 creator A5079384088 @default.
• W2904914487 date "2019-11-01" @default.
• W2904914487 modified "2023-10-05" @default.
• W2904914487 title "Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?" @default.
• W2904914487 cites W1827911007 @default.
• W2904914487 cites W2039511031 @default.
• W2904914487 cites W2080725537 @default.
• W2904914487 cites W2111347068 @default.
• W2904914487 cites W2115726304 @default.
• W2904914487 cites W2124539070 @default.
• W2904914487 cites W2179709561 @default.
• W2904914487 cites W2511949746 @default.
• W2904914487 cites W2514563112 @default.
• W2904914487 cites W2529092730 @default.
• W2904914487 cites W2551730987 @default.
• W2904914487 cites W2577453388 @default.
• W2904914487 cites W2583306764 @default.
• W2904914487 cites W2772730624 @default.
• W2904914487 cites W2793905111 @default.
• W2904914487 cites W2794378049 @default.
• W2904914487 cites W2795390114 @default.
• W2904914487 cites W2801556653 @default.
• W2904914487 cites W2809408990 @default.
• W2904914487 cites W2888836959 @default.
• W2904914487 cites W4242570784 @default.
• W2904914487 doi "https://doi.org/10.1016/j.euo.2018.11.009" @default.
• W2904914487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31411977" @default.
• W2904914487 hasPublicationYear "2019" @default.
• W2904914487 type Work @default.
• W2904914487 sameAs 2904914487 @default.
• W2904914487 citedByCount "21" @default.
• W2904914487 countsByYear W29049144872019 @default.
• W2904914487 countsByYear W29049144872020 @default.
• W2904914487 countsByYear W29049144872021 @default.
• W2904914487 countsByYear W29049144872022 @default.
• W2904914487 countsByYear W29049144872023 @default.
• W2904914487 crossrefType "journal-article" @default.
• W2904914487 hasAuthorship W2904914487A5004617137 @default.
• W2904914487 hasAuthorship W2904914487A5009118055 @default.
• W2904914487 hasAuthorship W2904914487A5016719534 @default.
• W2904914487 hasAuthorship W2904914487A5025981932 @default.
• W2904914487 hasAuthorship W2904914487A5045999238 @default.
• W2904914487 hasAuthorship W2904914487A5055737222 @default.
• W2904914487 hasAuthorship W2904914487A5057473966 @default.
• W2904914487 hasAuthorship W2904914487A5079384088 @default.
• W2904914487 hasConcept C121608353 @default.
• W2904914487 hasConcept C126322002 @default.
• W2904914487 hasConcept C126838900 @default.
• W2904914487 hasConcept C126894567 @default.
• W2904914487 hasConcept C143409427 @default.
• W2904914487 hasConcept C2775934546 @default.
• W2904914487 hasConcept C2776235491 @default.
• W2904914487 hasConcept C2780101318 @default.
• W2904914487 hasConcept C2780192828 @default.
• W2904914487 hasConcept C2781217009 @default.
• W2904914487 hasConcept C2781406297 @default.
• W2904914487 hasConcept C29456083 @default.
• W2904914487 hasConcept C2985322473 @default.
• W2904914487 hasConcept C71924100 @default.
• W2904914487 hasConceptScore W2904914487C121608353 @default.
• W2904914487 hasConceptScore W2904914487C126322002 @default.
• W2904914487 hasConceptScore W2904914487C126838900 @default.
• W2904914487 hasConceptScore W2904914487C126894567 @default.
• W2904914487 hasConceptScore W2904914487C143409427 @default.
• W2904914487 hasConceptScore W2904914487C2775934546 @default.
• W2904914487 hasConceptScore W2904914487C2776235491 @default.
• W2904914487 hasConceptScore W2904914487C2780101318 @default.
• W2904914487 hasConceptScore W2904914487C2780192828 @default.
• W2904914487 hasConceptScore W2904914487C2781217009 @default.
• W2904914487 hasConceptScore W2904914487C2781406297 @default.
• W2904914487 hasConceptScore W2904914487C29456083 @default.
• W2904914487 hasConceptScore W2904914487C2985322473 @default.
• W2904914487 hasConceptScore W2904914487C71924100 @default.
• W2904914487 hasIssue "6" @default.
• W2904914487 hasLocation W29049144871 @default.
• W2904914487 hasLocation W29049144872 @default.
• W2904914487 hasOpenAccess W2904914487 @default.
• W2904914487 hasPrimaryLocation W29049144871 @default.
• W2904914487 hasRelatedWork W1541131697 @default.
• W2904914487 hasRelatedWork W2032235093 @default.
• W2904914487 hasRelatedWork W2064191137 @default.
• W2904914487 hasRelatedWork W2099948048 @default.
• W2904914487 hasRelatedWork W2126091892 @default.
• W2904914487 hasRelatedWork W2134967293 @default.
• W2904914487 hasRelatedWork W2149157618 @default.
• W2904914487 hasRelatedWork W2566665866 @default.
• W2904914487 hasRelatedWork W2604277730 @default.
• W2904914487 hasRelatedWork W4248685099 @default.
• W2904914487 hasVolume "2" @default.

• next